[go: up one dir, main page]

FI111806B - Farmaceutiska kompositioner - Google Patents

Farmaceutiska kompositioner Download PDF

Info

Publication number
FI111806B
FI111806B FI20001749A FI20001749A FI111806B FI 111806 B FI111806 B FI 111806B FI 20001749 A FI20001749 A FI 20001749A FI 20001749 A FI20001749 A FI 20001749A FI 111806 B FI111806 B FI 111806B
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
tribasic
composition according
active ingredient
phosphate
Prior art date
Application number
FI20001749A
Other languages
English (en)
Finnish (fi)
Other versions
FI20001749L (sv
FI20001749A0 (sv
Inventor
Joseph Richard Creekmore
Norman Alfred Wiggins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI111806(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of FI20001749A0 publication Critical patent/FI20001749A0/sv
Publication of FI20001749L publication Critical patent/FI20001749L/sv
Application granted granted Critical
Publication of FI111806B publication Critical patent/FI111806B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (21)

1. Farmaceutisk komposition, kännetecknad därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]- 5 pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller ett farmaceutiskt godtagbart sait därav som aktiv bestandsdel och ett tribasiskt fosfatsalt, där katjonen ärflervärd.
2. Farmaceutisk komposition enligt patentkrav 1, kännetecknad därav, att det tribasiska fosfatsaltet, där katjonen är flervärd, är valt 10 bland tribasiskt kalciumfosfat, tribasiskt magnesiumfosfat och tribasiskt alumi-niumfosfat.
3. Farmaceutisk komposition enligt patentkrav 1 eller 2, kännetecknad därav, att det tribasiska fosfatsaltet, där katjonen är flervärd, är tribasiskt kalciumfosfat.
4. Farmaceutisk komposition enligt nagot av patentkraven 1-3, kännetecknad därav, att det tribasiska fosfatsaltets viktförhällande tili den aktiva beständsdelen är 1:80 - 50:1.
5. Farmaceutisk komposition enligt nägot av föregaende patentkrav, kännetecknad därav, att däri ytterligare ingär ett eller flera fyllmedel, 20 bindemedel, disintegreringsmedel eller smörjmedel.
6. Farmaceutisk komposition för oral administrering, kännetecknad därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2- ..il’ [metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra f*.. eller ett farmaceutiskt godtagbart sait därav som aktiv bestandsdel, ett eller fle- ·:··: 25 ra fyllmedel, ett eller flera bindemedel, ett eller flera disintegreringsmedel, ett eller flera smörjmedel och ett tribasiskt fosfatsalt, där katjonen är flervärd. * > ·
7. Farmaceutisk komposition enligt patentkrav 6, känneteck- • · · n a d därav, att den aktiva beständsdelen är närvarande i en mängd av .. §. t 1 - 80 % av kompositionens vikt. • I
8. Farmaceutisk komposition enligt patentkrav 6 eller 7, k ä n n e- • * tecknad därav, att det tribasiska fosfatsaltet är närvarande i en mängd av 1 - 50 % av kompositionens vikt.
9. Farmaceutisk komposition enligt patentkrav 6, 7 eller 8, k ä n n e-tecknad därav, att fyllmedlet är närvarande i en mängd av 30 - 90 % av f · · '. . 35 kompositionens vikt. » # is 111806
10. Farmaceutisk komposition enligt nägot av patentkraven 6-9, kännetecknad därav, att bindemedlet är närvarande i en mängd av 2-90 % av kompositionens vikt.
11. Farmaceutisk komposition enligt nägot av patentkraven 6-10, 5 kännetecknad därav, att disintegreringsmedlet är närvarande i en mängd av 2 - 10 % av kompositionens vikt.
12. Farmaceutisk komposition enligt nägot av patentkraven 6-11, kännetecknad därav, att smörjmedlet är närvarande i en mängd av 0,5 - 3 vikt-%.
13. Farmaceutisk komposition enligt patentkrav 6, känneteck nad därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metyl-sulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller ett farmaceutiskt godtagbart sait därav som aktiv beständsdel, tribasiskt kalcium-fosfat, mikrokristallin cellulosa, laktos, natriumstärkelseglykollat, butylerad hyd-15 roxitoluen och magnesiumstearat.
14. Farmaceutisk komposition enligt patentkrav 6, kännetecknad därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl- (metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller ett farmaceutiskt godtagbart sait därav som aktiv beständsdel, tribasiskt kal-20 ciumfosfat, povidon, mikrokristallin cellulosa, mannitol, natriumstärkelseglykollat, butylerad hydroxitoluen och magnesiumstearat.
, : 15. Farmaceutisk komposition enligt patentkrav 6, känneteck- n a d därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl- (metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller • ;..j 25 ett farmaceutiskt godtagbart sait därav som aktiv beständsdel, tribasiskt kal- .···. ciumfosfat, cros-povidon, mikrokristallin cellulosa, laktos och magnesiumstea- ,···, rat.
16. Farmaceutisk komposition enligt patentkrav 6, känneteck- .. . n a d därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl- 30 (metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller • · '·;·* ett farmaceutiskt godtagbart sait därav som aktiv beständsdel, tribasiskt kal- : ciumfosfat, povidon, mikrokristallin cellulosa, laktos, natriumstärkelseglykollat, :1 “; butylerad hydroxitoluen och magnesiumstearat.
17. Farmaceutisk komposition enligt nägot av föregäende patent-35 krav, kännetecknad därav, att den aktiva beständsdelen däri är kai- » » » » I 14 111806 ciumsaltet av (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydiOxihept-6-ensyra.
18. Användning av ett tribasiskt fosfatsalt, där katjonen är flervärd, för stabilisering av (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfo- 5 nyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller ett farma-ceutiskt godtagbart sait därav.
19. Användning enligt patentkrav 18, kännetecknad därav, att det tribasiska fosfatsaltet, där katjonen är flervärd, är valt bland tribasiskt kalciumfosfat, tribasiskt magnesiumfosfat och tribasiskt aluminiumfosfat.
20. Användning enligt patentkrav 18 eller 19, kän-netecknad därav, att det tribasiska fosfatsaltet, där katjonen är flervärd, är tribasiskt kalciumfosfat.
21 Förfarande för framställning av en stabilserad farmaceutisk komposition, kännetecknat därav, att ett tribasiskt fosfatsalt, där katjonen 15 är flervärd, inkorporeras i en farmaceutisk komposition, som innehäller fö-reningen (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]-pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller ett farmaceutiskt godtagbart sait därav. • 4 · > · · • l I * * 4 « · < f 1si • » I « 1 I · • · 1 • · • · • · I at > • 1 1 • I I I • I • I 1 • t i • » I t t 1 • I < • » • · * » a » ia • i « » I a
FI20001749A 2000-01-26 2000-08-04 Farmaceutiska kompositioner FI111806B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0001621 2000-01-26
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions

Publications (3)

Publication Number Publication Date
FI20001749A0 FI20001749A0 (sv) 2000-08-04
FI20001749L FI20001749L (sv) 2001-07-27
FI111806B true FI111806B (sv) 2003-09-30

Family

ID=9884259

Family Applications (3)

Application Number Title Priority Date Filing Date
FI20001749A FI111806B (sv) 2000-01-26 2000-08-04 Farmaceutiska kompositioner
FI20001750A FI121365B (sv) 2000-01-26 2000-08-04 Farmaceutisk komposition, som omfattar (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxi-6-heptensyra och förfarande för framställning därav
FI20105657A FI121589B (sv) 2000-01-26 2010-06-10 Farmaceutisk sammansättning som omfattar (E)-7[4-(4-fluorofenyl)-6-isopropyl-2[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxi-6-heptensyra

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI20001750A FI121365B (sv) 2000-01-26 2000-08-04 Farmaceutisk komposition, som omfattar (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxi-6-heptensyra och förfarande för framställning därav
FI20105657A FI121589B (sv) 2000-01-26 2010-06-10 Farmaceutisk sammansättning som omfattar (E)-7[4-(4-fluorofenyl)-6-isopropyl-2[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxi-6-heptensyra

Country Status (48)

Country Link
US (2) US6548513B1 (sv)
EP (6) EP2266540A1 (sv)
JP (3) JP3267960B2 (sv)
KR (3) KR100698333B1 (sv)
CN (3) CN101028268A (sv)
AP (2) AP1879A (sv)
AR (3) AR023624A1 (sv)
AT (3) AT412062B (sv)
AU (5) AU738074B2 (sv)
BE (2) BE1013413A3 (sv)
BG (4) BG65234B1 (sv)
BR (2) BR0003364A (sv)
CA (3) CA2639407C (sv)
CH (2) CH691347A5 (sv)
CL (1) CL2007001807A1 (sv)
CR (3) CR6568A (sv)
CZ (3) CZ290167B6 (sv)
DE (3) DE10038110B4 (sv)
DK (3) DK178242B1 (sv)
EE (3) EE05221B1 (sv)
ES (2) ES2171123B1 (sv)
FI (3) FI111806B (sv)
FR (2) FR2804025B1 (sv)
GB (3) GB0001621D0 (sv)
HK (4) HK1048950A1 (sv)
HR (3) HRP20020632B1 (sv)
HU (2) HUP0003111A3 (sv)
IL (4) IL147870A (sv)
IS (3) IS1940B (sv)
IT (2) ITTO20000779A1 (sv)
ME (4) ME00191B (sv)
MY (2) MY122707A (sv)
NL (2) NL1015859C2 (sv)
NO (4) NO312434B1 (sv)
NZ (2) NZ519774A (sv)
PL (2) PL341855A1 (sv)
PT (3) PT102504A (sv)
RS (1) RS50201B (sv)
RU (2) RU2264210C2 (sv)
SE (2) SE523471C2 (sv)
SI (1) SI1223918T1 (sv)
SK (2) SK11792000A3 (sv)
TR (3) TR200701171T2 (sv)
TW (2) TW553749B (sv)
UA (2) UA51853C2 (sv)
WO (2) WO2001054669A1 (sv)
YU (1) YU52902A (sv)
ZA (2) ZA200003997B (sv)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
ES2372682T5 (es) † 2000-04-10 2014-10-30 Teva Pharmaceutical Industries Ltd. Composiciones farmacéuticas estables que contienen ácidos 7-sustituidos-3,5-dihidroxiheptanoicos o ácidos 7-sustituidos-3,5-dihidroxiheptenoicos
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
WO2004016262A1 (ja) * 2002-08-12 2004-02-26 Kyowa Hakko Kogyo Co., Ltd. アミノ酸含有チュアブル錠
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
CA2657076A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
SG146608A1 (en) * 2003-09-12 2008-10-30 Amgen Inc Dw Us Rapid dissolution formulation of a calcium receptor-active compound
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1601658A1 (en) * 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
ES2364143T3 (es) * 2003-12-02 2011-08-25 Teva Pharmaceutical Industries Ltd. Estandar de referencia para caracterización de rosuvastatina.
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
AR048033A1 (es) * 2004-03-12 2006-03-22 Smithkline Beecham Plc Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
WO2005107722A2 (en) * 2004-05-04 2005-11-17 Rhodia Inc. Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
JP2007508379A (ja) * 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
CA2573316A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
CA2680693A1 (en) * 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
RU2303980C2 (ru) * 2005-06-03 2007-08-10 ОАО "Щелковский витаминный завод" Лекарственная форма с антиагрегационным действием и способ ее изготовления
AU2006278444A1 (en) * 2005-08-04 2007-02-15 Transform Pharmaceuticals, Inc. Novel formulations comprising fenofibrate and a statin, and related methods of treatment
JP2008515931A (ja) * 2005-08-16 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 結晶形ロスバスタチン中間体
CN101262847B (zh) 2005-09-12 2010-11-24 埃科特莱茵药品有限公司 包含嘧啶-磺酰胺的稳定性医药组合物
SG196789A1 (en) * 2005-10-31 2014-02-13 Kowa Co Pharmaceutical preparation having excellent photostability
WO2007071357A2 (en) * 2005-12-20 2007-06-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
US8455640B2 (en) * 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
HUE028475T2 (en) * 2006-10-09 2016-12-28 Msn Laboratories Private Ltd A novel process for the preparation of statins and their pharmaceutically acceptable salts
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
MX2009010925A (es) * 2007-04-09 2009-11-02 Scidose Llc Combinaciones de estatinas y agente anti-obesidad.
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
WO2009095934A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
CA2727630A1 (en) * 2008-06-13 2009-12-17 Glaxo Group Limited Pharmaceutical formulations
WO2009156173A1 (en) * 2008-06-27 2009-12-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising a statin
AU2008358622A1 (en) * 2008-06-27 2009-12-30 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EP2464344A2 (en) 2009-08-13 2012-06-20 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
JP5988963B2 (ja) * 2011-04-12 2016-09-07 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
CN107252420A (zh) * 2011-05-20 2017-10-17 阿斯利康(英国)有限公司 罗苏伐他汀钙的药物组合物
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
PL2851075T3 (pl) * 2012-05-14 2022-02-21 Shionogi & Co., Ltd. Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
US20160045497A1 (en) 2013-03-12 2016-02-18 Lg Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
KR20170083071A (ko) * 2014-11-11 2017-07-17 시오노기 앤드 컴파니, 리미티드 광에 대해서 불안정한 약물을 함유하는 다층 정제
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
WO2017070612A1 (en) 2015-10-23 2017-04-27 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
ES2963058T3 (es) 2015-12-08 2024-03-25 Lyndra Therapeutics Inc Configuraciones geométricas para sistemas de residencia gástrica
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
EP3518902A4 (en) 2016-09-30 2020-07-08 Lyndra, Inc. GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
AU2018279853B2 (en) 2017-06-09 2024-07-04 Nortiva Bio, Inc. Gastric residence systems with release rate-modulating films
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
EP0367895A1 (en) * 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
ES2064887T3 (es) 1990-09-13 1995-02-01 Akzo Nobel Nv Composiciones quimicas solidas estabilizadas.
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
SG45369A1 (en) 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DK0814782T3 (da) * 1995-12-22 2002-12-16 Nissan Chemical Ind Ltd Farmaceutisk præparat stabiliseret med et basisk middel
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
TR200003600T2 (tr) 1998-06-05 2001-04-20 Warner-Lambert Company ACE inhibitörleri içeren bileşimlerin magnezyum oksit kullanılarak sabitlenmesi
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1253921A4 (en) 2000-01-28 2004-10-13 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS

Also Published As

Publication number Publication date
CR10114A (es) 2008-08-21
SE0002827D0 (sv) 2000-08-04
US6316460B1 (en) 2001-11-13
AU5184200A (en) 2001-08-02
SE523481C2 (sv) 2004-04-20
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
NO312434B1 (no) 2002-05-13
EP2133070A1 (en) 2009-12-16
CN101028268A (zh) 2007-09-05
IS6480A (is) 2002-07-23
GB0019029D0 (en) 2000-09-27
EE200200052A (et) 2003-04-15
PL196808B1 (pl) 2008-02-29
AP1449A (en) 2005-07-28
BE1013414A5 (fr) 2001-12-04
GB2358582B (en) 2004-09-29
TR200200270T2 (tr) 2002-06-21
DE60001371T2 (de) 2004-01-22
PT102503A (pt) 2000-12-29
WO2001054669A1 (en) 2001-08-02
DE10038108A1 (de) 2001-08-02
SI1223918T1 (en) 2003-06-30
CN1282581A (zh) 2001-02-07
EE05586B1 (et) 2012-10-15
ATA13612000A (de) 2004-02-15
HK1040936B (zh) 2010-06-11
CH691347A5 (de) 2001-07-13
CZ299105B6 (cs) 2008-04-23
ME00202B (me) 2010-10-10
BE1013413A3 (fr) 2001-12-04
DE10038110B4 (de) 2006-06-29
IL150513A0 (en) 2003-02-12
EE05221B1 (et) 2009-10-15
NO20003968L (no) 2001-07-27
HU222578B1 (hu) 2003-08-28
EP1223918A1 (en) 2002-07-24
BG66159B1 (bg) 2011-09-30
JP3267960B2 (ja) 2002-03-25
JP4800988B2 (ja) 2011-10-26
FI20001750A0 (sv) 2000-08-04
MEP33808A (hr) 2010-10-10
RU2206324C1 (ru) 2003-06-20
EE200200411A (et) 2003-12-15
AU5184100A (en) 2001-08-02
UA51853C2 (uk) 2002-12-16
ZA200003997B (en) 2000-08-14
CA2315141C (en) 2009-08-18
FR2804025A1 (fr) 2001-07-27
DE10038110A1 (de) 2001-08-23
JP2007182452A (ja) 2007-07-19
CL2007001807A1 (es) 2008-01-18
FI20001749L (sv) 2001-07-27
FI121365B (sv) 2010-10-29
RS50201B (sr) 2009-07-15
IL150513A (en) 2012-12-31
EP2774609A1 (en) 2014-09-10
KR20000072135A (ko) 2000-12-05
IS2805B (is) 2012-09-15
HRP20020632B1 (en) 2010-12-31
HUP0003111A2 (hu) 2002-02-28
HU0003110D0 (en) 2000-10-28
AU2005202392C1 (en) 2016-06-02
BR0003364A (pt) 2001-09-18
BG106393A (en) 2002-07-31
NO20003967D0 (no) 2000-08-04
AR023624A1 (es) 2002-09-04
BG65234B1 (bg) 2007-09-28
CA2639407A1 (en) 2001-07-26
NL1015859C2 (nl) 2001-10-16
UA77156C2 (en) 2006-11-15
ITTO20000779A1 (it) 2002-02-04
EP1223918B1 (en) 2003-02-05
CA2315141A1 (en) 2001-07-26
DK178242B1 (da) 2015-09-28
HRP20020097B1 (hr) 2010-12-31
NO20003967L (no) 2001-07-27
NO20071303L (no) 2001-07-27
FR2804025B1 (fr) 2002-08-23
AU781269C (en) 2006-11-30
FI20105657L (sv) 2010-06-10
BR0003365A (pt) 2001-09-18
TR200201888T2 (tr) 2002-11-21
EP2018853A1 (en) 2009-01-28
CZ20002883A3 (cs) 2000-10-11
CA2313783C (en) 2002-03-12
FR2795324B1 (fr) 2002-05-17
AP2002002409A0 (en) 2002-03-31
FI20001750L (sv) 2001-07-27
CN100528161C (zh) 2009-08-19
PL341855A1 (en) 2001-07-30
MY123650A (en) 2006-05-31
PT102503B (pt) 2004-02-27
CR6568A (es) 2004-03-05
KR20010077840A (ko) 2001-08-20
CA2639407C (en) 2011-09-13
NZ531474A (en) 2007-04-27
IL147870A0 (en) 2002-08-14
KR100698333B1 (ko) 2007-03-23
HK1036935A1 (en) 2002-01-25
AU781269B2 (en) 2005-05-12
NO327554B1 (no) 2009-08-10
SE523471C2 (sv) 2004-04-20
EE200900047A (et) 2011-04-15
HK1200368A1 (en) 2015-08-07
ES2171123B1 (es) 2003-11-16
TR200701171T2 (tr) 2007-04-24
NO20003968D0 (no) 2000-08-04
AT412062B (de) 2004-09-27
ATA13602000A (de) 2004-02-15
ME00191B (me) 2010-10-10
GB2358582A (en) 2001-08-01
ITTO20000779A0 (it) 2000-08-04
TWI228050B (en) 2005-02-21
YU5202A (sh) 2004-12-31
WO2001054668A1 (en) 2001-08-02
MY122707A (en) 2006-04-29
JP2001206847A (ja) 2001-07-31
IL187416A0 (en) 2008-02-09
AU6580000A (en) 2001-08-07
NZ519774A (en) 2004-04-30
JP4800467B2 (ja) 2011-10-26
GB2358583B (en) 2002-02-06
HU0003111D0 (en) 2000-10-28
KR100388713B1 (ko) 2003-06-25
DE60001371D1 (de) 2003-03-13
AT412063B (de) 2004-09-27
NO327675B1 (no) 2009-09-07
EP2266540A1 (en) 2010-12-29
NL1015858C2 (nl) 2001-07-27
AU2000264559A1 (en) 2001-08-07
MEP33708A (hr) 2010-10-10
BG106926A (bg) 2003-04-30
FI121589B (sv) 2011-01-31
GB2358583A (en) 2001-08-01
SE0002827L (sv) 2001-07-27
ZA200003998B (en) 2000-08-14
JP2001206877A (ja) 2001-07-31
PT102504A (pt) 2001-07-31
YU52902A (sh) 2006-01-16
HUP0003111A3 (en) 2003-03-28
HRP20080525A2 (en) 2008-12-31
EE04990B1 (et) 2008-04-15
US6548513B1 (en) 2003-04-15
CA2313783A1 (en) 2000-10-16
NO2010005I1 (no) 2010-05-03
DK200001171A (da) 2001-07-27
NL1015859A1 (nl) 2001-07-27
SK283872B6 (sk) 2004-03-02
TW553749B (en) 2003-09-21
DK200001170A (da) 2001-01-27
IS8620A (is) 2007-03-07
SE0002826D0 (sv) 2000-08-04
HK1047052A1 (zh) 2003-02-07
AU2005202392A1 (en) 2005-06-30
FR2795324A1 (fr) 2000-12-29
CN1319396A (zh) 2001-10-31
AU2005202392B2 (en) 2008-11-20
SE0002826L (sv) 2001-07-27
HRP20020632A2 (en) 2004-12-31
AR060248A2 (es) 2008-06-04
BG110353A (en) 2009-09-30
AU738074B2 (en) 2001-09-06
HK1040936A1 (zh) 2002-06-28
RU2002122752A (ru) 2004-03-10
ATE232088T1 (de) 2003-02-15
HK1048950A1 (zh) 2003-04-25
SK11782000A3 (sk) 2001-12-03
ES2171123A1 (es) 2002-08-16
HK1036934A1 (en) 2002-01-25
IL147870A (en) 2003-10-31
PT1223918E (pt) 2003-06-30
FI20001749A0 (sv) 2000-08-04
HUP0003110A2 (hu) 2001-05-28
RU2264210C2 (ru) 2005-11-20
KR20030036492A (ko) 2003-05-09
CZ290167B6 (cs) 2002-06-12
CZ298411B6 (cs) 2007-09-26
EP1251831A1 (en) 2002-10-30
CN1149997C (zh) 2004-05-19
HUP0003110A3 (en) 2003-02-28
AR025055A1 (es) 2002-11-06
CR6687A (es) 2005-07-18
AP1879A (en) 2008-08-14
ES2155043B1 (es) 2001-12-01
DK1223918T3 (da) 2003-04-28
BG66168B1 (bg) 2011-10-31
GB0019028D0 (en) 2000-09-27
PL341853A1 (en) 2001-01-29
SK11792000A3 (sk) 2001-12-03
CZ20002884A3 (cs) 2001-09-12
AP2002002591A0 (en) 2002-09-30
IS1940B (is) 2004-07-16
ITTO20000780A1 (it) 2000-11-04
IS6254A (is) 2002-01-29
GB0001621D0 (en) 2000-03-15
CH700184B1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
FI111806B (sv) Farmaceutiska kompositioner
MXPA00007656A (en) Pharmaceutical compositions
HK1034673A (en) Pharmaceutical compositions
HK1149489A (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
HK1139059A (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
HK1128409A (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Legal Events

Date Code Title Description
MA Patent expired